Quoin Pharmaceuticals Files Proxy Statement

TL;DR

QUOI proxy filing is out, standard shareholder comms.

AI Summary

Quoin Pharmaceuticals, Ltd. (formerly Cellect Biotechnology Ltd. and Cellect Biomed Ltd.) is filing a Definitive Proxy Statement (DEFA14A) on April 2, 2024. This filing is related to the company's proxy materials for its shareholders. The company is incorporated in L3 and its principal business address is in Kfar Saba, Israel.

Why It Matters

This filing is a standard regulatory requirement for public companies to communicate with shareholders regarding important company matters, such as annual meetings and voting procedures.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new material financial information or strategic decisions.

Key Players & Entities

• Quoin Pharmaceuticals, Ltd. (company) — Registrant
• Cellect Biotechnology Ltd. (company) — Former company name
• Cellect Biomed Ltd. (company) — Former company name
• 23 HATA'AS STREET (address) — Business and Mail Address
• Kfar Saba (location) — City

FAQ

Filing Documents

• tm2410426d1_defa14a.htm (DEFA14A) — 10KB
• tm2410426d1_defa14aimg001.jpg (GRAPHIC) — 4KB
• 0001104659-24-042329.txt ( ) — 17KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement. Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). Definitive Proxy Statement. Definitive Additional Materials. Soliciting Material under § 240.14a-12. Quoin Pharmaceuticals Ltd. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. The following material supplements the definitive proxy statement (the “Proxy Statement”) of Quoin Pharmaceuticals Ltd., an Israeli company (the “Company”), filed with the Securities and Exchange Commission (the “SEC”) on February 27, 2024 relating to the Company’s Special General Meeting of Shareholders (the “Special Meeting”), previously scheduled to be held on March 29, 2024. The Company’s Special Meeting was called to order at 12:00 pm, Eastern Time, on March 29, 2024, and adjourned, without any business being conducted due to lack of the required quorum, to April 5, 2024. The Special Meeting will reconvene at 12:00 pm, Eastern Time, on Friday, April 5, 2024, at the offices of Blank Rome LLP, located at One Logan Square, Philadelphia, PA 19103. Only shareholders of record as of the record date, February 23, 2024, are entitled to and are being requested to vote at the Special Meeting. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting, unless properly revoked, and shareholders who have previously submitted a proxy or otherwise voted need not take any action. No changes have been made to the record date or the proposal to be brought before the Special Meeting, which is set forth in the Proxy Proxy Statement and other proxy materials relating to the Special Meeting, which are available free of charge on the SEC’s website at www.sec.gov and on https://quoinpharma.gcs-web.com/special-meetings. Information contained on or accessible through these websites is not incorporated by reference in, or otherwise made a part of, the Proxy This supplement should be read in conjunction with the Proxy Statement in its entirety.

View Full Filing

View this DEFA14A filing on SEC EDGAR